Aptargroup, Inc. (ATR) Stock Price & Analysis
Aptargroup, Inc. (ATR) fell 0.70% to USD 127.41 as of September 8, 2026 at 04:59 UTC, according to Nexqual real-time market data.
ATR last closed at USD 127.41; the session ranged USD 126.53–128.47 on volume of 323,957 shares. Market capitalization is —, with a 52-week range of USD 103.23–146.91 (NYQ). Source: Nexqual, September 8, 2026 at 04:59 UTC.
Key Statistics (as of September 8, 2026 at 04:59 UTC)
| Price | USD 127.41 |
|---|---|
| Change | ▼ 0.70% (down) |
| Previous Close | USD 127.41 |
| Open | USD 127.41 |
| Day Range | USD 126.53 – 128.47 |
| 52-Week Range | USD 103.23 – 146.91 |
| Volume | 323,957 shares |
| Market Cap | — |
| Exchange | NYQ |
Technical Analysis (ATR)
Nexqual's technical model rates ATR "SELL" based on 2 bullish and 5 bearish signals across 128 daily candles, as of September 8, 2026 at 04:59 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 35.69 (neutral) |
| vs SMA50 | Below (USD 131.23) |
| MACD | -0.57 (negative) |
Analyst Ratings (ATR)
Wall Street analysts rate ATR "None" based on 7 analysts, with a mean price target of USD 170.14 (range USD 155–220), per Nexqual as of September 8, 2026 at 04:59 UTC.
| Consensus Rating | None |
|---|---|
| Analyst Count | 7 |
| Mean Target | USD 170.14 |
| High Target | USD 220 |
| Low Target | USD 155 |
| Buy / Hold / Sell | 7 / 1 / 0 |
From Aptargroup, Inc.'s Latest SEC 10-K Filing (filed 2026-02-06)
Key Strengths & Strategy (as disclosed to the SEC)
- Leveraging our proprietary polymer-based technologies, we enable enhanced mitigation of impurities and degradation, product stability, shelf life, and performance across medical device, drug delivery, and selected food protection applications.
- While we expect that these types of new products will come to market in the future, it is difficult to estimate when, as the rigors of pharmaceutical regulations affect the timing of product introductions by our pharmaceutical customers that use our proprietary drug delivery systems.
- We have developed a multi-dose dispensing device suitable for ophthalmic formulations.
- Although Europe represents the largest region for us in terms of sales, our beauty and pharmaceutical customers often export their finished products using our technology around the world for consumption.
Partnerships
- Historically, the environmental impact of these processes has been minimal, and we collaborate with local permitting authorities to ensure we operate responsibly.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| SLGN | Silgan Holdings Inc. | USD 41.18 | ▼ 0.36% |
| DCI | Donaldson Company, Inc. | USD 91.03 | ▲ 1.25% |
| CSL | Carlisle Companies Incorporated | USD 352.14 | ▲ 2.99% |
| SON | Sonoco Products Company | USD 51.95 | ▼ 5.1% |
| BRC | Brady Corporation | USD 90.21 | ▲ 0.03% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 04:59 UTC. This page is informational and not investment advice.